

We Claim:

1. A method of inhibiting cancer development comprising the administration to a subject in need thereof of an effective amount of a fatty acid synthase inhibitor.

5

2. A method according to claim 1 wherein the subject is a mammal.

3. A method according to claim 1 wherein the subject is a human.

- 10 4. A method according to claim 1 wherein the subject has pre-cancerous lesions.

5. A method according to claim 5 wherein the pre-cancerous lesions express fatty acid synthase.

15


6. A method according to claim 5 wherein the pre-cancerous lesions express the *neu* protein.

7. A method according to claim 5 wherein the pre-cancerous lesions express fatty acid synthase and the *neu* protein.

20

8. A method according to claim 5 wherein the pre-cancerous lesions are in a tissue type selected from the group consisting of breast, prostate, colon, lung, stomach, mouth, and bile duct.
- 5 9. A method according to claim 8 wherein the tissue type is breast.
10. A method according to claim 8 wherein the tissue type is prostate.
11. A method according to claim 8 wherein the tissue type is colon.
- 10 12. A method according to claim 8 wherein the tissue type is lung.
13. A method according to claim 8 wherein the tissue type is stomach.
- 15 14. A method according to claim 8 wherein the tissue type is mouth.
15. A method according to claim 8 wherein the tissue type is bile duct.
16. A method according to claim 1 wherein the effective amount is in the
20 range from about 60 mg/kg to about 7.5 mg/kg per day.
17. A method according to claim 1 wherein the fatty acid synthase inhibitor is a compound that directly inhibits the fatty acid synthase enzyme.


18. A method according to claim 1 wherein the fatty acid synthase inhibitor is a compound having the following formula:



wherein:

- 10 $R^1 = \text{H, C}_1\text{-C}_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, } -\text{CH}_2\text{OR}^5, -\text{C(O)R}^5, -\text{CO(O)R}^5, -\text{C(O)NR}^5\text{R}^6, -\text{CH}_2\text{C(O)R}^5, \text{ or } -\text{CH}_2\text{C(O)NHR}^5, \text{ where } R^5 \text{ and } R^6 \text{ are each independently H, C}_1\text{-C}_{10} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms.}$
- 15 $R^2 = -\text{OH, } -\text{OR}^7, -\text{OCH}_2\text{C(O)R}^7, -\text{OCH}_2\text{C(O)NHR}^7, -\text{OC(O)R}^7, -\text{OC(O)OR}^7, -\text{OC(O)NR}^7\text{R}^8, \text{ where } R^7 \text{ and } R^8 \text{ are each independently H, C}_1\text{-C}_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where } R^7 \text{ and } R^8 \text{ can each optionally contain halogen atoms;}$
- $R^3 \text{ and } R^4, \text{ the same or different from each other, are C}_1\text{-C}_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.}$

19. A method according to claim 1 wherein the fatty acid synthase inhibitor is a compound having the following formula:



R^9 = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{11}$, -
 $C(O)OR^{11}$, $-C(O)R^{11}$, $-CH_2C(O)OR^{11}$, $-CH_2C(O)NHR^{11}$, where R^{11} is H or C_1 -

5 C_{10} alkyl, cycloalkyl, or alkenyl;

R^{10} = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X = $-OR^{12}$, or $-NHR^{12}$, where R^{12} is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl,
 arylalkyl, or alkylaryl, the R^{12} group optionally containing a carbonyl group,
 a carboxyl group, a carboxamide group, an alcohol group, or an ether
 10 group, the R^{12} group further optionally containing one or more halogen
 atoms;

with the proviso that when R^9 is $=CH_2$, then X is not $-OH$.

20. A method according to claim 1 wherein the fatty acid synthase inhibitor is
 15 tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid.